Progress of PARP inhibitors in breast cancer / 肿瘤研究与临床

ABSTRACT

PARP inhibitors are a kind of anticancer drugs approved for the clinical treatment of ovarian cancer and primary peritoneal cancer on the basis of the strategy of synthetic lethality. With the publication of two phase Ⅲ clinical trials results, the indications for PARP inhibitors have been expanded to advanced breast cancer with germline BRCA-1/2 mutations. However, the current exploration of PARP inhibitors in breast cancer is still at early stage. This article summarizes the anticancer mechanism of PARP inhibitors and new advances in treatment of breast cancer.